Skip to main content
HUAPONT LIFE SCIENCES CO., LTD. logo

HUAPONT LIFE SCIENCES CO., LTD. — Investor Relations & Filings

Ticker · 002004 ISIN · CNE000001JJ6 LEI · 3003009TGXJC0JJVTJ07 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,461 across all filing types
Latest filing 2020-09-21 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002004

About HUAPONT LIFE SCIENCES CO., LTD.

https://www.huapont.com.cn

HUAPONT LIFE SCIENCES CO., LTD. operates as a diversified entity specializing in the research, development, manufacturing, and distribution of pharmaceutical and chemical solutions. The company holds a prominent position in the dermatology sector, providing a comprehensive range of therapeutic products for various skin disorders. Its pharmaceutical operations extend to the production of high-quality active pharmaceutical ingredients (APIs) and finished dosage forms. Beyond human health, the organization maintains a significant footprint in the agrochemical sector, focusing on the development and supply of crop protection products, including herbicides and pesticides. The company also integrates healthcare services into its business model, overseeing the operation of medical facilities and specialized clinics. Its strategic focus centers on technological advancement and the maintenance of a robust supply chain to support its global commercial activities.

Recent filings

Filing Released Lang Actions
独立董事关于公司对深圳普瑞金生物药业有限公司增资并收购其部分股权暨关联交易的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on a related party transaction involving the company's investment and acquisition of shares in another company. It references compliance with governance guidelines and legal procedures, and provides an independent judgment approving the transaction. This type of document is typically part of governance disclosures related to board or management decisions, rather than a full financial report, earnings release, or regulatory filing. It is not a general regulatory announcement or a report publication notice. Therefore, the best fitting category is Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board or senior management regarding significant corporate actions.
2020-09-21 Chinese
关于对深圳普瑞金生物药业有限公司增资并收购其部分股权暨关联交易的公告
Capital/Financing Update Classification · 100% confidence The document is a detailed announcement regarding a company's investment and acquisition of equity in another company, including specifics about the transaction, related party information, pricing, agreements, and the impact on the company. It discusses the strategic rationale, approval processes, and includes financial data of the target company. The document is not a financial report like an annual or interim report, nor is it a call transcript or audit report. It is a capital/financing update about a significant investment and acquisition transaction. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail confirm it is the announcement itself, not a brief notice or a report publication announcement.
2020-09-21 Chinese
独立董事关于公司对深圳普瑞金生物药业有限公司增资并收购其部分股权暨关联交易的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors regarding a proposed related-party transaction involving capital increase and acquisition of shares in another company. It references a board meeting to be held on a specific date to discuss the transaction. The content is an opinion and approval from independent directors prior to the board meeting, not a full report or financial statement. It is related to board/management information about a corporate transaction and governance oversight. The document length is short and it is not an announcement of voting results or a proxy solicitation. Therefore, the best fitting category is Board/Management Information (MANG).
2020-09-21 Chinese
关于参与投资产业基金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 华邦生命健康股份有限公司 regarding its participation in an investment in an industry fund (产业基金). It details the investment amount, partners, fund structure, management fees, profit distribution, risks, and impact on the company. The document is a formal announcement of a capital investment transaction, describing the company's financing activity and capital allocation. It does not contain financial statements, quarterly or annual results, or audit information. It is not a report but an announcement of a financing/investment update. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (5499 characters) and content support this classification with high confidence.
2020-09-21 Chinese
关于控股股东股份质押及解除质押的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the pledge and release of shares by the controlling shareholder and related parties. It details the number of shares pledged, the proportion of shares involved, pledge start and end dates, and other related information. There is no financial statement, earnings data, or management discussion. The document is a formal disclosure about share pledging activities, which fits the category of Capital/Financing Update (CAP). The document length is 3616 characters, which is relatively short but contains substantive information about financing activities (share pledges). Therefore, it is not a mere announcement of a report but a direct update on capital structure changes related to share pledging.
2020-09-14 Chinese
关于全资子公司药品阿伐斯汀胶囊通过仿制药一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Huabang Life Health Co., Ltd. regarding its wholly-owned subsidiary's drug (Avastin capsules) passing the generic drug consistency evaluation by the National Medical Products Administration. It includes details about the drug, regulatory approval, impact on the company, and risk warnings. The document is short (1077 characters) and is an announcement of a regulatory approval event rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or management analysis. It is not a report publication announcement since it is not announcing the release of a report but rather a regulatory approval event. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about product approval and company impact, which does not fit other specific categories.
2020-09-07 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.